Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary…
By S. Cohen, P. Emery, M. Greenwald, M. Dougados, R. Furie, M. Genovese, E. Keystone, J. Loveless, G. Burmester, M. Cravets and 3 more. Arthritis & Rheumatism, 2006
1,735 citations recorded by the source corpus.
Subfields: Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/2903f52f9f5884f52946e0897be86abf5a28f799
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Rheumatology
Citations in the corpus
- Therapeutic antibodies for autoimmunity and inflammation (2010, background): “Rituximab, a chimeric CD20-specific antibody, was approved in 2005 for the treatment of patients with rheumatoid arthritis who had inadequate responses to TNF blockad”
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update (2010, positive): “—There is high-level evidence from one RCT each that abatacept, golimumab, rituximab and tocilizumab are effective in patients for whom TNF inhibitor therapy has failed”
- Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen (2012, positive): “2012 Vol. 209 No. 11 2065-2077 www.jem.org/cgi/doi/10.1084/jem.20112272 2065 Self-antigen–specific B cells are pathogenic in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (Cohen et al., 2006; Mandik-Nayak et al., 2008; Shlomchik, 2008).”